GSK2118436: Interim Phase I/II data

Interim data from a subgroup of 10 melanoma patients in a Phase I/II trial showed that twice-daily 150 mg oral GSK2118436 led to a median PFS of 8.3 months. GSK2118436 was well tolerated up to twice-daily 150 mg, with dose-limiting toxicities of pyrexia and syncope observed at the twice-daily 200 mg dose. The most commonly reported all-grade adverse events were fatigue, headache, skin lesions and nausea, with low-grade cutaneous squamous cell carcinoma (SCC) reported as the most common >=grade 3 adverse event. The trial enrolled 93 patients, including 76 patients with mutant BRAF melanoma, to receive 12-400 mg/day GSK2118436. Data were presented at the Society for Melanoma Research meeting in Sydney. ...